NasdaqGM:NAMSBiotechs
NewAmsterdam Pharma (NAMS) On EU Backing Is The Pullback Leaving Shares Mispriced
NewAmsterdam Pharma (NAMS) is back in focus after regulators in Europe issued a positive opinion on Ubeslo and Evlarco, two obicetrapib based treatments for primary hypercholesterolemia and mixed dyslipidemia.
See our latest analysis for NewAmsterdam Pharma.
Despite the positive regulatory update, NewAmsterdam Pharma’s share price has been under pressure recently. The 30 day share price return is down 20.21% and the year to date share price return is down 21.05%, while the 1 year total...